Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.
Level 1 - systematic review of randomized trials
Meta-analysis of randomized controlled trials
PubMed 32084455 · doi:10.1016/j.diabres.2020.108087
What was done
The authors conducted an updated meta-analysis of randomized controlled trials comparing glucagon-like peptide-1 receptor agonists (GLP1-RA) against other therapies, calculating pooled Mantel-Haenszel odds ratios (MH-OR) with 95% confidence intervals for the risk of cholelithiasis.
What was found
GLP-1 receptor agonist therapy significantly increased the risk of cholelithiasis compared with control therapies (MH-OR 1.28, 95% CI [1.11, 1.48]). No other numbers or subgroup data are provided in the abstract.
Why it matters
This updated meta-analysis confirms that GLP-1 receptor agonist use is associated with a modestly increased risk of gallstone disease across randomized trials.
Limits
The abstract does not report the number of included trials, total participant count, specific GLP-1 receptor agonist drugs evaluated, comparator types, treatment duration, absolute risk increase, or heterogeneity assessments.
Cited by
- supports GLP-1 receptor agonist medications increase the risk of gallstones.